These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21163865)

  • 1. Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarction.
    Maitland-van der Zee AH; van Wieren-de Wijer DB; de Boer A; Kroon AA; de Leeuw PW; Schiffers P; Janssen RG; Psaty BM; van Duijn CM; Stricker BH; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):208-14. PubMed ID: 21163865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Pharmacogenomics J; 2008 Dec; 8(6):400-7. PubMed ID: 18347611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives.
    Bozkurt O; Verschuren WM; van Wieren-de Wijer BM; Knol MJ; de Boer A; Grobbee DE; Geerlings MI; Heerdink ER; Klungel OH
    J Hum Hypertens; 2008 Nov; 22(11):774-80. PubMed ID: 18563171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.
    Schelleman H; Klungel OH; Witteman JC; Breteler MM; Yazdanpanah M; Danser AH; Hofman A; van Duijn CM; de Boer A; Stricker BH
    Eur J Hum Genet; 2007 Apr; 15(4):478-84. PubMed ID: 17299437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
    Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis.
    Xi B; Zeng T; Liu L; Liang Y; Liu W; Hu Y; Li J
    Breast Cancer Res Treat; 2011 Nov; 130(2):561-8. PubMed ID: 21638051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic interactions of renin-angiotensin system genes in myocardial infarction.
    Araújo MA; Goulart LR; Cordeiro ER; Gatti RR; Menezes BS; Lourenço C; Silva HD
    Int J Cardiol; 2005 Aug; 103(1):27-32. PubMed ID: 16061119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age.
    Franco E; Palumbo L; Crobu F; Anselmino M; Frea S; Matullo G; Piazza A; Trevi GP; Bergerone S
    BMC Med Genet; 2007 May; 8():27. PubMed ID: 17519002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy.
    Smilde TD; Zuurman MW; Hillege HL; van Veldhuisen DJ; van Gilst WH; van der Steege G; Voors AA; Kors JA; de Jong PE; Navis G
    Am J Hypertens; 2007 Oct; 20(10):1097-103. PubMed ID: 17903694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease.
    Buraczyńska M; Pijanowski Z; Spasiewicz D; Nowicka T; Sodolski T; Widomska - Czekajska T; Ksiazek A
    Kardiol Pol; 2003 Jan; 58(1):1-9. PubMed ID: 14502296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of angiotensin II type-1 receptor 1166A/C with angiotensin-converting enzyme polymorphism on risk of acute myocardial infarction in north Indians.
    Kaur R; Das R; Ahluwalia J; Kumar RM; Talwar KK
    J Renin Angiotensin Aldosterone Syst; 2012 Dec; 13(4):440-5. PubMed ID: 22392878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study.
    Etminan M; Zhang B; Fitzgerald M; Brophy JM
    Pharmacotherapy; 2006 Apr; 26(4):479-82. PubMed ID: 16553505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ; Gums JG
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure.
    Wu CK; Luo JL; Tsai CT; Huang YT; Cheng CL; Lee JK; Lin LY; Lin JW; Hwang JJ; Chiang FT
    Pharmacogenomics J; 2010 Feb; 10(1):46-53. PubMed ID: 19752885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction.
    Jeron A; Hengstenberg C; Engel S; Löwel H; Riegger GA; Schunkert H; Holmer S
    Eur Heart J; 2001 Apr; 22(8):663-8. PubMed ID: 11286523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
    Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
    J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant.
    Peters BJ; Maitland-van der Zee AH; Stricker BH; van Wieren-de Wijer DB; de Boer A; Kroon AA; de Leeuw PW; Schiffers P; Janssen RG; van Duijn CM; Klungel OH
    Pharmacogenet Genomics; 2008 Jul; 18(7):631-6. PubMed ID: 18551043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.